Loading...
Loading...
Cardium Therapeutics
CXM
today announced that it has entered into its first international agreement for
the commercialization of Excellagen in the South Korean market. Cardium
entered into a marketing and distribution agreement with BL&H Co. Ltd., an
established pharmaceutical company based in Korea, for the commercialization
of Excellagen Formulated Fibrillar Collagen Gel in the South Korean market
under a transfer price arrangement as further described below.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in